CK Life Sciences Int'l., (Holdings) Inc. announced that its subsidiary Sequencio Therapeutics Company Limited has had two abstracts selected for presentation at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place 4-8 November 2026 in Phoenix, Arizona. The presentations will detail preclinical findings from two lead cancer vaccine programmes, offering the international immuno-oncology community a first look at data generated under Sequencio's Prime–Infiltrate–Ignite–Translate (PINT) translational research framework. The announcement, distributed via Media OutReach Newswire, signals that both vaccine candidates are moving closer to human clinical testing.
The significance of the data lies in how the two programmes address persistent obstacles in cancer immunotherapy: enabling the immune system to recognise and attack cancer cells, and countering the mechanisms tumours use to evade immune responses. The first programme, CKLS118, combines a TROP2 circular RNA vaccine with checkpoint inhibition. In preclinical models, the combination significantly increased activated IFN-γ-positive CD4+ and CD8α+ T-cell subsets within tumours, indicating greater local immune activation. In the 4T1-hTROP2 model, tumour growth inhibition reached 74.7% and 88.9% when the vaccine was combined with 0.3 and 1.0 mg/kg anti-PD-1, respectively, compared with 28.9% and 68.6% with anti-PD-1 alone. These results support further development of CKLS118 with checkpoint inhibition and the evaluation of a potential dose-sparing strategy, which could matter for reducing toxicity and cost in future treatment regimens.
The second programme, CKLS202, is a dual-antigen vaccine co-targeting human PD-L1 and PRAME, designed to integrate tumour recognition and immune modulation within a single vaccine. In humanised models, vaccination induced robust PRAME-specific T-cell responses, anti-human PD-L1 antibody titres above 1:16,000 and functional hPD-1/hPD-L1 blockade. In the efficacy model, vaccination achieved 65% tumour growth inhibition and was associated with increased tumour-infiltrating CD4+ cells (from 0.94% to 2.97%), more than twofold increases in interferon-γ and granzyme B, and a more than fivefold reduction in the M2 macrophage marker CD163, consistent with a shift toward a more immune-active tumour environment. Vaccinated tumour-free mice were also protected against tumour rechallenge, supporting durable antigen-specific immunity.
Dr Melvin Toh, Vice President and Chief Scientific Officer of CK Life Sciences, said the findings provide preclinical evidence supporting the intended mechanisms of action of the vaccines and demonstrate how the programmes may generate and sustain anti-tumour immune responses. He noted that the findings may also help inform future clinical development in peri-operative settings, where lower tumour burden may give vaccine-induced immunity a greater opportunity to control residual disease. The use of humanised preclinical models under the Translate element of the PINT framework is intended to help researchers assess how the findings may be relevant to humans, a critical step before first-in-human studies.
Both posters are scheduled for presentation on 6 November 2026. The selection of two abstracts by SITC underscores external scientific interest in Sequencio's approach and positions the CK Life Sciences subsidiary to engage with global immuno-oncology experts as it pursues its stated goal of shifting cancer treatment from transient tumour reduction toward sustained, immune-controlled remission.
